LPCN NASDAQ
Lipocine Inc.
1W: -2.4%
1M: -13.1%
3M: -17.0%
YTD: -74.4%
1Y: -31.0%
3Y: -29.3%
5Y: -89.0%
$2.05
-0.02 (-0.97%)
Weekly Expected Move ±5.4%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-10-18
Earliest Filing
2024-04-26
Latest Filing
partner: 10
Counterparties (Filed by LPCN)
10 relationshipsCompanies named in LPCN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| A.G.P./Alliance Global Partners | — | partner | Sales Agent for the issuance and sale of the Company's common stock. | 2024-04-26 | View |
| Verity Pharmaceuticals, Inc. | — | partner | Exclusive licensee for TLANDO franchise in the U.S. and Canada | 2024-01-18 | View |
| Gordon Silver Limited | — | partner | Co-announcer of the licensing agreement with Lipocine and Verity Pharma | 2024-01-18 | View |
| Antares Pharma, Inc. | — | partner | Lipocine Inc. amended an exclusive license agreement for TLANDO product rights in the US, extending the option deadline | 2022-04-01 | View |
| Antares Pharma, Inc. | — | partner | Exclusive U.S. licensing partner for TLANDO commercialization | 2021-10-18 | View |
| Teva Pharmaceutical Industries, Ltd. | TEVJF | partner | Strategic alliance partner mentioned in Antares Pharma portfolio | 2021-10-18 | View |
| AMAG Pharmaceuticals | — | partner | Strategic alliance partner mentioned in Antares Pharma portfolio | 2021-10-18 | View |
| Pfizer Inc. | PFE | partner | Strategic alliance partner mentioned in Antares Pharma portfolio | 2021-10-18 | View |
| Idorsia Pharmaceuticals Ltd. | — | partner | Strategic alliance partner mentioned in Antares Pharma portfolio | 2021-10-18 | View |
| Ferring Pharmaceuticals | — | partner | Licensor of NOCDURNA to Antares Pharma | 2021-10-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-16 | Other Events; Exhibits | View | |
| 2026-09-14 | Other Events; Exhibits | View | |
| 2026-09-11 | Other Events | View | |
| 2026-09-10 | Other Events; Exhibits | View | |
| 2026-08-21 | Officer/Director Change | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-08-03 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-12 | Other Events; Exhibits | View | |
| 2026-06-04 | Other Events; Exhibits | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-26 | Other Events; Exhibits | View | |
| 2026-05-19 | Other Events; Exhibits | View | |
| 2026-05-18 | Other Events; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-21 | Officer/Director Change | View | |
| 2026-04-02 | Other Events; Exhibits | View | |
| 2026-04-02 | Other Events; Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-18 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR